{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"77.5","upperLimit":"98.2","value":"91.7"},{"groupId":"OG001","lowerLimit":"58.8","upperLimit":"88.2","value":"75.7"},{"groupId":"OG002","lowerLimit":"73.0","upperLimit":"91.2","value":"83.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"37"},{"groupId":"OG002","value":"73"}],"units":"Participants"}],"description":"ORR: Percentage of participants with confirmed complete response (CR; negative immunofixation on the serum and urine, disappearance of any soft tissue plasmacytomas, and ≤5% plasma cells in bone marrow), partial response (PR; ≥50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by ≥90% or to ≤200 mg per 24 hour; if serum and urine M-protein are unmeasurable, a ≥50% decrease in the difference between involved and uninvolved free light chain (FLC\\] levels is required in place of the M-protein criteria; if serum and urine M-protein are unmeasurable, and serum FLC is also unmeasurable, a ≥50% reduction in plasma cells is required in place of M-protein, provided baseline bone marrow plasma cell percentage was ≥30%; and, if present at baseline, a ≥50% reduction in the size of soft tissue plasmacytomas), very good PR (VGPR; normal FLC ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence), or stringent CR (sCR; CR plus VGPR).","dispersionType":"95% Confidence Interval","groups":[{"description":"Elotuzumab 10 mg/kg administered as an IV infusion in combination with lenalidomide 25 mg and dexamethasone 40 mg administered orally","id":"OG000","title":"Elotuzumab 10 mg/kg + Lenalidomide and Dexamethasone (Phase 2)"},{"description":"Elotuzumab 20 mg/kg administered as an IV infusion in combination with lenalidomide 25 mg and dexamethasone 40 mg administered orally.","id":"OG001","title":"Elotuzumab 20 mg/kg + Lenalidomide and Dexamethasone (Phase 2)"},{"description":"Elotuzumab (10 or 20 mg/kg) administered as an IV infusion in combination with lenalidomide 25 mg and dexamethasone 40 mg administered orally.","id":"OG002","title":"Total (Phase 2)"}],"paramType":"NUMBER","populationDescription":"Safety population: All randomized participants who received at least 1 dose of study drug","reportingStatus":"POSTED","timeFrame":"From date of randomization until 60 days following the last infusion (or before initiation of new therapy), up to 101 months","title":"Objective Response Rate (ORR) According to the International Myeloma Working Group Uniform Response Criteria (Phase 2)","type":"PRIMARY","unitOfMeasure":"percentage of participants"}